重新评估轻度创伤性脑损伤出血进展风险:抗凝与抗血小板治疗的作用
该回顾性队列研究纳入2312例轻度TBI合并创伤性颅内出血成人患者,按mBIG标准分类后再按出血特征重新分类(RmBIG,排除抗凝/抗血小板状态)。结果显示仅基于抗凝/抗血小板用药归为mBIG 3的患者出血进展率(11.9%)显著低于基于出血严重程度归类者(18.1%,p<0.001),华法林是唯一与影像学进展显著相关的药物(OR 1.93,p=0.01)。
要点
- 仅因使用抗凝/抗血小板药物被归为mBIG 3的患者出血进展风险低于因出血严重程度归为mBIG 3者。
- 华法林是唯一与影像学出血进展显著相关的药物(OR 1.93,p=0.01)。
- 抗凝/抗血小板状态整体未显著增加手术干预或院内死亡率。
核心结论
- 抗凝和抗血小板治疗可能不应自动将所有轻度TBI患者归为高风险。
- 华法林代表风险谱高端,但多数药物未增加不良结局。
研究设计与样本
- 回顾性队列研究,纳入2016-2021年一级创伤中心2312例轻度TBI(GCS 13-15)合并创伤性颅内出血的成人患者。
- 患者先按mBIG标准分类,再按出血特征重新分类为RmBIG(排除抗凝/抗血小板状态)。
主要发现
- mBIG 3患者影像学进展率为14.1%,mBIG 1和2分别为1.7%和6.8%。
- 在相同RmBIG分类内,使用抗凝/抗血小板药物者与未使用者出血进展率相似。
- 仅基于抗凝/抗血小板使用归为mBIG 3者出血进展率为11.9%,显著低于基于出血严重程度归类者的18.1%(p<0.001)。
- 抗凝/抗血小板状态整体与手术干预率和院内死亡率无差异。
- 亚组分析中,华法林是唯一与影像学出血进展显著相关的药物(OR 1.93,p=0.01)。
关键数值与推荐
- mBIG 3患者影像学进展率为14.1%,mBIG 1为1.7%,mBIG 2为6.8%。
- 仅基于抗凝/抗血小板使用归为mBIG 3者出血进展率为11.9%,基于出血严重程度归类者为18.1%(p<0.001)。
- 华法林与影像学出血进展相关(OR 1.93,p=0.01)。
临床怎么用
- 对于轻度TBI合并颅内出血患者,可考虑结合出血特征而非仅凭抗凝/抗血小板用药进行风险分层。
- 使用华法林的患者可能需要更密切的监测和影像学随访。
- 多数抗凝/抗血小板药物未显著增加不良结局,或可优化住院资源和重复影像策略。
局限性
- 回顾性单中心研究,可能存在选择偏倚和混杂因素。
- 亚组分析中部分药物样本量可能有限,需谨慎解读。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In patients with mild traumatic brain injury (TBI; Glasgow Coma Scale scores 13-15), the presence of anticoagulant or antiplatelet therapy, collectively referred to as blood thinners (BTs), has been presumed to elevate the risk of intracranial hemorrhage (ICH) progression. Current Brain Injury Guidelines (BIG) automatically classify all patients receiving BTs as high-risk (modified BIG [mBIG] 3), requiring hospital admission and repeat imaging. The aim of this study was to evaluate whether BTs independently increase the risk of hemorrhage progression, surgical intervention, or mortality in mild TBI with ICH, and whether risk varies by specific BT agent. METHODS: The authors conducted a retrospective cohort study of 2312 adult patients presenting with mild TBI and traumatic ICH at a level 1 trauma center (2016-2021). Patients were categorized by mBIG criteria and then reclassified using hemorrhage characteristics (reclassified mBIG [RmBIG]), excluding BT status. Outcomes included radiographic progression, surgical intervention, and in-hospital mortality. A subgroup analysis was performed to assess outcomes by specific BT type. RESULTS: Radiographic progression occurred in 14.1% of mBIG 3 patients versus 1.7% and 6.8% of mBIG 1 and 2 patients, respectively. Among reclassified patients, those receiving BTs had similar progression rates to non-BT patients within the same RmBIG category. Patients classified as mBIG 3 based only on BT use had significantly lower progression rates (11.9%) compared with those classified based on hemorrhage severity (18.1%, p < 0.001). Mortality and surgical intervention rates did not differ overall by BT status. In the BT subgroup analysis, warfarin was the only agent significantly associated with increased radiographic progression (OR 1.93, p = 0.01). CONCLUSIONS: Anticoagulant and antiplatelet therapy might not warrant automatic classification of all patients with mild TBI as high risk. While warfarin represents the upper end of the risk spectrum, most agents did not increase adverse outcomes. Refining BIG to incorporate hemorrhage features and agent-specific risk might improve patient care and resource utilization.
引用
- Harland TA, Topp G, Prabhala T, et al. Reassessing the risk of hemorrhage progression in mild traumatic brain injury: the role of anticoagulant and antiplatelet therapy. J Neurosurg. 2026. PMID: 42537244. doi:10.3171/2026.2.JNS252985
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。